Bharat Biotech’s Nucelion and VeGen Bio Partner to Manufacture Advanced Dual-Target CAR-T Cancer Therapy in India

India’s emerging cell and gene therapy industry has taken an important step forward with a strategic partnership between Nucelion Therapeutics, a wholly owned subsidiary of Bharat Biotech, and Hyderabad-based VeGen Bio to develop manufacturing capabilities for an advanced cancer treatment. Announced on 21 October 2026, the collaboration focuses on technology transfer, clinical manufacturing and future commercial production of a dual-target Chimeric Antigen Receptor T-cell (CAR-T) therapy for multiple myeloma, a serious form of blood cancer.

The partnership will initially concentrate on VeGen Bio’s lead therapeutic candidate, VL-2511, an experimental autologous CAR-T therapy designed to target two proteins associated with malignant cells. Unlike conventional CAR-T treatments that generally recognise a single target, VL-2511 is designed to recognise both B-cell maturation antigen (BCMA) and CD19. The dual-target approach aims to reduce the ability of cancer cells to escape immune recognition by altering or losing one of the targeted proteins.

Under the agreement, Nucelion will serve as VeGen Bio’s technology-transfer and manufacturing partner, providing specialised infrastructure and expertise for the therapy’s development. The companies intend to advance VL-2511 towards Phase 1/2 clinical trials in India while preparing the manufacturing processes required for potential commercial production. VeGen Bio is targeting commercialisation in 2028, subject to successful clinical development and regulatory approval.

Hyderabad Companies Join Forces to Advance Cell Therapy Manufacturing

The collaboration brings together two companies operating in different but complementary areas of biotechnology. Nucelion Therapeutics specialises in contract research, development and manufacturing services for cell and gene therapies, while VeGen Bio focuses on precision oncology and the development of advanced treatments for serious diseases.

Nucelion operates as a specialised Contract Research, Development and Manufacturing Organisation (CRDMO), providing technical services that help biotechnology companies translate experimental therapies into products suitable for clinical investigation and potential commercial production. Its capabilities include process development, advanced biological manufacturing, analytical testing and quality-control systems designed for complex therapeutic products.

VeGen Bio contributes the scientific expertise and therapeutic technology associated with VL-2511. The company’s research focuses on developing engineered cellular treatments that can recognise specific biological targets involved in cancer and other serious diseases. Through the partnership, VeGen Bio will gain access to specialised manufacturing infrastructure without independently establishing all the facilities required for advanced cell therapy production.

The agreement establishes a coordinated development pathway in which scientific research, process development and manufacturing preparation can progress together. This approach is particularly important for cellular therapies because their clinical development depends on highly specialised manufacturing methods and strict controls over product quality.

VL-2511 Targets Two Cancer-Associated Proteins

The central focus of the partnership is VL-2511, a dual-target CAR-T therapy being developed for multiple myeloma. The disease originates in plasma cells, a specialised type of white blood cell responsible for producing antibodies. When plasma cells become cancerous, they can accumulate in the bone marrow and interfere with normal blood-cell production and immune function.

Multiple myeloma can cause anaemia, bone damage, kidney complications and increased susceptibility to infections. Although several modern treatment approaches have improved outcomes, the disease remains difficult to cure, and patients may experience relapse after initially responding to therapy. Researchers are therefore exploring new immunotherapies capable of producing more durable responses.

VL-2511 is designed to recognise both BCMA and CD19. BCMA is a protein commonly expressed on plasma cells and is an established target for several advanced multiple myeloma treatments. CD19 is another protein associated with B-cell biology and is widely studied in cellular immunotherapy.

By engineering immune cells to recognise both targets, researchers hope to address one of the challenges associated with single-target treatments. The proposed mechanism could allow the modified immune cells to recognise malignant cells displaying either of the relevant antigens, although the clinical effectiveness of this approach must be established through appropriately designed studies.

Understanding CAR-T Cell Therapy

CAR-T cell therapy is a form of cancer immunotherapy that uses genetically modified immune cells to identify and attack malignant cells. The treatment typically begins by collecting T lymphocytes, a type of immune cell, from a patient’s blood through a specialised procedure.

Scientists then modify these cells in a controlled laboratory environment so that they express a synthetic receptor called a Chimeric Antigen Receptor. The receptor enables the engineered T cells to recognise selected proteins associated with cancer cells.

Following genetic modification, the cells undergo controlled expansion to produce the quantity required for treatment. The manufacturing process includes extensive testing to assess cell identity, purity, viability and other quality characteristics before the treatment can be administered.

The engineered cells are subsequently infused into the patient, where they are intended to identify and attack cells displaying the targeted antigens. In some patients with certain blood cancers, CAR-T therapies have produced substantial and durable clinical responses.

However, CAR-T therapy is a complex medical intervention that requires specialised clinical facilities and careful monitoring. Potential complications include cytokine release syndrome, neurological adverse effects, infections and prolonged reductions in certain blood-cell populations. These risks make specialist supervision and comprehensive safety assessment essential.

Dual-Target Technology Aims to Address Antigen Escape

One of the challenges associated with CAR-T therapy is antigen escape, a biological process through which cancer cells become less recognisable to the engineered immune cells.

Conventional CAR-T therapies generally target a specific protein on the surface of malignant cells. Some cancer cells may survive treatment by reducing or losing expression of that protein, potentially allowing the disease to recur despite an earlier therapeutic response.

Dual-target CAR-T technology seeks to address this challenge by engineering immune cells to recognise two separate antigens. The approach may make it more difficult for certain cancer cells to avoid immune recognition through changes involving only one target.

VL-2511 incorporates this strategy by combining BCMA and CD19 recognition within a single therapeutic platform. The companies believe that the dual-target design could provide advantages for patients with multiple myeloma, including those with difficult-to-treat disease.

Nevertheless, the ability of this technology to improve long-term outcomes will depend on clinical evidence. Researchers must establish whether the dual-target approach provides meaningful benefits in effectiveness, durability and safety compared with existing treatments.

Clinical Development Underway in International Markets

According to the companies, VL-2511 has accumulated clinical experience in China and is undergoing clinical development in the United States. The therapy is described as a Phase II clinical-stage candidate, with the developers reporting encouraging observations from earlier investigations.

VeGen Bio has highlighted clinical activity in patients with extramedullary disease, a difficult form of multiple myeloma in which malignant plasma cells develop outside the bone marrow. Such cases can present additional treatment challenges and are associated with significant unmet medical needs.

The company has also reported a favourable safety profile in its clinical investigations. These observations remain company-reported findings, and larger controlled studies will be important for determining the treatment’s effectiveness and risks across different patient populations.

The Nucelion partnership is intended to support the next stage of development in India. The companies aim to establish the technical and manufacturing capabilities required for Indian clinical trials while working towards the regulatory requirements applicable to advanced cellular therapies.

The proposed Phase 1/2 programme in India will require the appropriate regulatory permissions and clinical arrangements before patient enrolment can begin.

Nucelion’s Manufacturing Facility to Support Advanced Cell Therapies

A major component of the agreement involves transferring VL-2511’s manufacturing technology to Nucelion’s specialised Good Manufacturing Practice (GMP) facility in Hyderabad.

The facility incorporates segregated cell-processing areas, environmental monitoring systems and infrastructure designed for the handling of genetically modified cellular products. These capabilities are necessary because advanced cell therapies involve living biological materials that require carefully controlled processing conditions.

Unlike conventional pharmaceutical products manufactured in large batches, autologous CAR-T therapies use cells obtained from individual patients. Each manufacturing process must therefore preserve the identity of the patient’s cells throughout collection, processing, storage and delivery.

Nucelion’s facility incorporates chain-of-identity and chain-of-custody systems intended to ensure that patient-linked cellular materials remain correctly identified at every stage of manufacturing. These controls are essential for preventing mix-ups and maintaining product traceability.

The manufacturing infrastructure is designed with the regulatory expectations of India’s Central Drugs Standard Control Organisation, the United States Food and Drug Administration and the European Medicines Agency in mind. Compliance with applicable standards will remain subject to the relevant regulatory assessments and approvals.

Technology Transfer Will Cover Complex Manufacturing Processes

Under the partnership, Nucelion will undertake a range of activities required to establish and improve VL-2511’s manufacturing process. These include process development, analytical method development, cell processing, genetic modification, cryopreservation and product testing.

Technology transfer involves moving the technical knowledge, manufacturing procedures and analytical methods associated with a therapeutic product from the developer to the manufacturing organisation. For advanced cell therapies, this process must ensure that the transferred manufacturing method consistently produces cells meeting defined quality requirements.

Nucelion will also support vector-enabled transduction, a process through which genetic instructions are introduced into T cells so that they can produce the intended chimeric antigen receptors. This stage requires careful control because the efficiency and consistency of genetic modification can influence the characteristics of the resulting cellular product.

Following processing and expansion, the engineered cells must undergo appropriate quality testing before being released for clinical use. Cryopreservation techniques are used to maintain cell viability during storage and transportation under controlled conditions.

By integrating these activities within a specialised manufacturing environment, the companies aim to establish a dependable production process capable of supporting clinical development and potential future commercial manufacturing.

Partnership Focuses on Improving Manufacturing Efficiency

One of the principal objectives of the collaboration is to improve the manufacturing efficiency of advanced cell therapies and reduce the costs associated with their production.

CAR-T therapies are among the more complex biological treatments because manufacturing often involves processing a separate batch of cells for each patient. Specialised equipment, trained personnel, biological raw materials and extensive quality testing contribute to production costs.

Nucelion and VeGen Bio intend to optimise manufacturing procedures, improve production yields and strengthen operational efficiency. These measures could help reduce resource requirements while maintaining the stringent quality standards associated with cellular therapies.

The companies also plan to examine opportunities for improving process consistency and reducing manufacturing delays. Greater efficiency in these areas could support the development of a more sustainable domestic production model.

Improved manufacturing economics alone will not determine the final cost of treatment. Clinical procedures, hospital infrastructure, patient monitoring, regulatory requirements and distribution arrangements will also influence affordability.

Nevertheless, developing specialised manufacturing capacity in India could strengthen the domestic supply chain and reduce reliance on overseas facilities for certain stages of advanced therapy production.

Bharat Biotech Expands Beyond Conventional Vaccine Manufacturing

The partnership represents another development in Bharat Biotech’s expansion into advanced biological manufacturing through Nucelion Therapeutics.

Bharat Biotech is internationally recognised for its vaccine research and manufacturing capabilities. Through Nucelion, the company is developing specialised infrastructure and services for cell therapies, gene therapies and other complex biological products.

These technologies differ considerably from conventional vaccines, but both fields require expertise in biological processing, quality assurance, manufacturing validation and regulatory compliance.

Nucelion has been developing its cell and gene therapy business through collaborations involving regenerative medicine, advanced biological production systems and emerging therapeutic technologies.

In January 2026, the company announced a collaboration with Bengaluru-based Pandorum Technologies involving experimental regenerative therapies for eye diseases. Nucelion has also pursued international partnerships relating to cellular technologies and RNA manufacturing.

The VeGen Bio agreement extends these activities into the development and manufacturing of engineered immune-cell therapies for cancer.

Potential Applications Beyond Multiple Myeloma

Although multiple myeloma is the initial focus of VL-2511, the developers are also investigating the therapy’s potential applications in other conditions.

According to the companies, the candidate is undergoing clinical investigation for POEMS syndrome, a rare disorder associated with abnormal plasma cells and multiple systemic complications.

The therapy is also being studied for selected autoimmune conditions, including systemic lupus erythematosus. Autoimmune diseases arise when the immune system mistakenly attacks the body’s own tissues, creating inflammation and potentially affecting multiple organs.

Researchers are investigating whether engineered cellular therapies can modify or eliminate immune-cell populations involved in certain autoimmune disorders. This approach differs from conventional treatments that generally suppress broader immune activity.

The potential applications remain experimental, and the clinical benefits and risks must be assessed separately for each disease. Results from studies involving one condition cannot automatically establish effectiveness in another.

The wider research programme nevertheless demonstrates the scientific interest in applying engineered immune-cell technologies beyond their established roles in selected blood cancers.

India’s Growing Capabilities in CAR-T Therapy Development

India has already made important progress in developing indigenous CAR-T treatments through collaborations involving academic institutions, hospitals and biotechnology companies.

A notable achievement was the development of NexCAR19, an indigenous CD19-directed CAR-T therapy created through collaboration involving the Indian Institute of Technology Bombay, Tata Memorial Centre and ImmunoACT.

The treatment received Indian regulatory approval in 2023 for specified indications involving B-cell malignancies, marking an important milestone in the country’s advanced cancer treatment capabilities.

The development demonstrated that Indian researchers and biotechnology companies could establish domestic systems for designing, manufacturing and clinically evaluating sophisticated cellular therapies.

The Nucelion–VeGen Bio partnership builds on this expanding ecosystem while pursuing a different technological approach. VL-2511 is being developed as a dual-target treatment for multiple myeloma, whereas NexCAR19 targets CD19 for certain B-cell cancers.

India’s growing experience in advanced therapeutic development provides opportunities for specialised manufacturing organisations, research institutions and clinical centres to participate in new treatment programmes.

Targeting Commercialisation by 2028

VeGen Bio has identified 2028 as its target for potential commercialisation of VL-2511. Achieving this objective will depend on the progress of clinical trials, successful manufacturing development and the completion of applicable regulatory procedures.

The companies must establish that the treatment can be manufactured consistently while meeting defined quality and safety requirements. Clinical investigations will also need to generate evidence supporting the therapy’s effectiveness and acceptable risk profile in the intended patient population.

Regulatory review will be an essential stage before any commercial introduction in India. Advanced cellular therapies require detailed assessments covering manufacturing processes, product characteristics, clinical outcomes and long-term patient safety.

The partnership is intended to establish the necessary manufacturing infrastructure early in the development process, allowing technical preparation to progress alongside clinical research.

The planned commercialisation timeline represents the companies’ development objective rather than confirmation of a future product launch.

Building India’s Advanced Cell and Gene Therapy Ecosystem

The collaboration between Nucelion Therapeutics and VeGen Bio reflects the increasing participation of Indian biotechnology companies in advanced therapeutic research and manufacturing.

Cell and gene therapies require a combination of scientific innovation, specialised production infrastructure, trained technical personnel and experienced clinical institutions. Their development also depends on regulatory systems capable of evaluating complex biological products.

By combining VeGen Bio’s therapeutic technology with Nucelion’s manufacturing capabilities, the partnership seeks to strengthen several of these components within India.

The companies also intend to establish a framework that could support additional therapeutic candidates from VeGen Bio’s research pipeline. Such an arrangement would allow future programmes to use established manufacturing systems and technical expertise rather than developing entirely separate infrastructure for each product.

The agreement represents a significant step towards building domestic capabilities for sophisticated cellular medicines. As India’s biotechnology ecosystem continues to develop, collaborations of this kind can support the transition from laboratory research to clinical manufacturing and, ultimately, approved therapeutic products.

The advancement of VL-2511 will provide an important test of India’s ability to manufacture complex dual-target CAR-T therapies while addressing the challenges of clinical validation, quality control and treatment accessibility.

---

References

1. Nucelion Therapeutics and VeGen Bio, company announcement, 21 October 2026. Strategic collaboration for technology transfer, clinical manufacturing and commercial production of VL-2511.
2. Business Standard, 21 October 2026. Bharat Biotech Arm, VeGen Bio to Manufacture Advanced Cancer Treatment.
   https://www.business-standard.com/companies/news/nucelion-vegen-bio-car-t-manufacturing-multiple-myeloma-126102100640_1.html
3. Express Pharma, 21 October 2026. Nucelion Therapeutics, VeGen Bio Collaborate on CAR-T Cell Therapy Manufacturing.
   https://www.expresspharma.in/nucelion-therapeutics-vegen-bio-collaborate-on-car-t-cell-therapy-manufacturing/
4. BioSpectrum India, 21 October 2026. Nucelion Therapeutics and VeGen Bio Partner to Build End-to-End Pathway for Cell Therapy Innovation.
   https://www.biospectrumindia.com/news/109/28689/nucelion-therapeutics-and-vegen-bio-partner-to-build-end-to-end-pathway-for-cell-therapy-innovation.html
5. ETPharma, 21 October 2026. VeGen Bio Teams Up with Nucelion Therapeutics to Advance Dual-Target Myeloma CAR-T.
   https://pharma.economictimes.indiatimes.com/news/pharma-industry/vegen-bio-teams-up-with-nucelion-therapeutics-to-advance-dual-target-myeloma-car-t/135088950
6. Pharmabiz, 21 October 2026. Bharat Biotech’s Nucelion and VeGen Bio to Build End-to-End Pathway for Cell Therapy Innovation.
   https://pharmabiz.com/NewsDetails.aspx?aid=191384&sid=2

---